Head & Neck Cancers | Specialty

Dr. Burtness on the Effectiveness of Immunotherapy in Head and Neck Cancers

March 31st 2020

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Frontline Avelumab Falls Short in Phase III Head and Neck Cancer Study

March 13th 2020

The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free survival in patients with untreated locally advanced squamous cell carcinoma of the head and neck.

FDA Grants Breakthrough Designation to Debio 1143 in Frontline Head and Neck Cancer

February 27th 2020

The FDA has granted a breakthrough therapy designation to Debio 1143, an inhibitor of apoptosis protein antagonist, for the treatment of patients with previously untreated, unresectable, locally advanced squamous cell carcinoma of the head and neck in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy

Remote Monitoring Enhances Care for Patients With Head and Neck Cancer

February 21st 2020

If clinicians can identify complications earlier and take appropriate prophylactic or therapeutic measures, treatment plan adherence and outcomes may be improved for patients with head and neck cancer.

FDA Grants Priority Review to Selpercatinib for RET Fusion+ NSCLC and Thyroid Cancers

January 29th 2020

The FDA has granted a priority review designation to a new drug application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

NICE Rejects Treatments for Head and Neck Cancer and AML

January 16th 2020

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

Frontline Pembrolizumab Regimens Receive Japanese Approval in Head and Neck Cancer

December 20th 2019

Japan's Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer.

Giants of Cancer Care Inductee Announced as Next ASCO President

December 19th 2019

Everett E. Vokes, MD, FASCO, who is a Giants of Cancer Care® recipient for Head and Neck Cancer, has been named the next president of ASCO for the 2021 to 2022 term.

Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck Cancer

November 27th 2019

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

Dr. Gross on the Prognosis of Cutaneous Squamous Cell Carcinoma of the Head and Neck

November 22nd 2019

Neil D. Gross, MD, FACS, discusses the prognosis of patients who are diagnosed with cutaneous squamous cell carcinoma of the head and neck.

Pembrolizumab Regimens Approved in EU for Frontline PD-L1+ HNSCC

November 20th 2019

The European Commission has approved pembrolizumab as a monotherapy or in combination with platinum and 5-FU chemotherapy for the frontline treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression (composite positive score ≥1) on their tumors.

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

Dr. Saba on Anticipated Research in Head and Neck Cancer

October 31st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

SITC Introduces Guidelines for Anti–PD-1 Therapy in HNSCC

October 31st 2019

Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic head and neck squamous cell carcinoma.

EU Panel Backs Pembrolizumab Regimens for Frontline HNSCC

October 18th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab as a monotherapy or in combination with platinum and 5-FU as frontline treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma and PD-L1 expression on their tumors.

Notable RET Inhibitor Trials Underway

October 18th 2019

The Next Steps in RET Inhibitor Research

October 18th 2019

Using RET Inhibitors in Clinical Practice

October 18th 2019

RET Inhibitor Trial Updates at ASCO and ESMO

October 18th 2019

How BLU-667 Has Changed the Treatment Landscape

October 18th 2019